BioXcel Therapeutics has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for BXCL501 (dexmedetomidine) for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.
Read the link a little and saw that it works via modulating alpha(2a)-adrenergic receptor. That receptor regulates norepinephrine
The link talks about norepinephrine having a role in depression and anxiety. So it makes a lot of sense that norepinephrine plays a role in SCZ
It makes sense that an SCZ will react much worse to delusions/hallucinations/paranoia if they also have an anxiety problem.
You should know also that clozapine is also an alpha(2a)-adrenergic receptor antagonist. So this drug will hopefully work . . .